Gabrielle T. Prince

3.1k total citations
28 papers, 263 citations indexed

About

Gabrielle T. Prince is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Gabrielle T. Prince has authored 28 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 13 papers in Genetics and 10 papers in Oncology. Recurrent topics in Gabrielle T. Prince's work include Acute Myeloid Leukemia Research (18 papers), Acute Lymphoblastic Leukemia research (8 papers) and CAR-T cell therapy research (8 papers). Gabrielle T. Prince is often cited by papers focused on Acute Myeloid Leukemia Research (18 papers), Acute Lymphoblastic Leukemia research (8 papers) and CAR-T cell therapy research (8 papers). Gabrielle T. Prince collaborates with scholars based in United States, France and Switzerland. Gabrielle T. Prince's co-authors include Ivana Gojo, B. Douglas Smith, Amy E. DeZern, Jonathan Webster, Mark J. Levis, Amanda L. Blackford, Leo Luznik, Ravi Varadhan, Ivan Borrello and Howard Streicher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurosurgery.

In The Last Decade

Gabrielle T. Prince

25 papers receiving 263 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gabrielle T. Prince United States	9	155	114	82	80	46	28	263
Sanbin Wang China	9	102 0.7×	137 1.2×	74 0.9×	52 0.7×	49 1.1×	31	259
Álex Bataller United States	10	208 1.3×	90 0.8×	131 1.6×	46 0.6×	93 2.0×	51	319
Anna Sicuranza Italy	11	142 0.9×	94 0.8×	73 0.9×	71 0.9×	71 1.5×	40	295
M Martín-Ayuso Spain	9	164 1.1×	66 0.6×	110 1.3×	127 1.6×	54 1.2×	10	280
Nicolaus Kroeger Germany	10	259 1.7×	98 0.9×	73 0.9×	56 0.7×	90 2.0×	42	336
Tiziana Moscato Italy	13	269 1.7×	174 1.5×	86 1.0×	64 0.8×	40 0.9×	33	339
Sajad Khazal United States	10	151 1.0×	138 1.2×	66 0.8×	42 0.5×	39 0.8×	33	322
Hanna A. Knaus Austria	8	183 1.2×	149 1.3×	87 1.1×	182 2.3×	35 0.8×	21	317
Corina Schneidawind Germany	12	118 0.8×	84 0.7×	138 1.7×	101 1.3×	25 0.5×	25	302
Daniel Egan United States	8	127 0.8×	123 1.1×	79 1.0×	49 0.6×	33 0.7×	22	212

Countries citing papers authored by Gabrielle T. Prince

Since Specialization

Citations

This map shows the geographic impact of Gabrielle T. Prince's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabrielle T. Prince with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabrielle T. Prince more than expected).

Fields of papers citing papers by Gabrielle T. Prince

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabrielle T. Prince. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabrielle T. Prince. The network helps show where Gabrielle T. Prince may publish in the future.

Co-authorship network of co-authors of Gabrielle T. Prince

This figure shows the co-authorship network connecting the top 25 collaborators of Gabrielle T. Prince. A scholar is included among the top collaborators of Gabrielle T. Prince based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabrielle T. Prince. Gabrielle T. Prince is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mo, Shirley, Alexander J. Ambinder, Amy E. DeZern, et al.. (2025). DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors. Blood. 146(Supplement 1). 1710–1710.

Webster, Jonathan, Mark J. Levis, Ivana Gojo, et al.. (2025). Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML. PubMed. 2(4). 100133–100133. 1 indexed citations

Li, Daniel, B. Douglas Smith, Mark J. Levis, et al.. (2024). Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias. Blood. 144(Supplement 1). 5904–5904.

DiNardo, Courtney D., Gail J. Roboz, Justin M. Watts, et al.. (2024). Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Advances. 8(15). 4209–4220. 21 indexed citations

DiNardo, Courtney D., Gail J. Roboz, Justin M. Watts, et al.. (2023). P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME. HemaSphere. 7(S3). e75740ab–e75740ab. 3 indexed citations

Sanber, Khaled, Hua‐Ling Tsai, Jonathan Webster, et al.. (2023). Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. Leukemia & lymphoma. 64(4). 846–855. 3 indexed citations

Webster, Jonathan, Richard J. Jones, Amanda L. Blackford, et al.. (2023). A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance. Blood. 142(Supplement 1). 3582–3582. 1 indexed citations

DiNardo, Courtney D., Gail J. Roboz, Justin M. Watts, et al.. (2023). MDS-457 Ivosidenib in Mutant IDH1 Relapsed/Refractory Myelodysplastic Syndrome: Updated Substudy Results. Clinical Lymphoma Myeloma & Leukemia. 23. S366–S367. 1 indexed citations

Karantanos, Theodoros, Hua‐Ling Tsai, Lukasz P. Gondek, et al.. (2022). Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leukemia & lymphoma. 63(8). 1942–1948. 8 indexed citations

10.

Schüpper, Alexander J., Rebecca M. Baron, William W. L. Cheung, et al.. (2022). 213 5-Aminolevulinic Acid for Enhanced Surgical Visualization of High-Grade Gliomas: A Prospective, Multicenter Study. Neurosurgery. 68(Supplement_1). 65–65. 9 indexed citations

11.

Webster, Jonathan, Meera Yogarajah, Marianna Zahurak, et al.. (2021). A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia & lymphoma. 62(13). 3181–3191. 3 indexed citations

12.

Gojo, Ivana, Robert K. Stuart, Jonathan Webster, et al.. (2019). Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients. Blood. 134(Supplement_1). 832–832. 57 indexed citations

13.

Webster, Jonathan, Richard F. Ambinder, Richard J. Jones, et al.. (2019). A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance. Blood. 134(Supplement_1). 778–778. 3 indexed citations

14.

Webster, Jonathan, Marlise R. Luskin, Gabrielle T. Prince, et al.. (2018). Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study. Blood. 132(Supplement 1). 557–557. 36 indexed citations

15.

Robinson, Tara M., Gabrielle T. Prince, Christopher J. Thoburn, et al.. (2018). Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leukemia & lymphoma. 59(12). 2801–2811. 9 indexed citations

16.

Norsworthy, Kelly J., Amy E. DeZern, Hua-Ling Tsai, et al.. (2017). Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature. Leukemia Research. 61. 25–32. 8 indexed citations

17.

Goswami, Meghali, Gabrielle T. Prince, Angélique Biancotto, et al.. (2017). Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy. Journal of Translational Medicine. 15(1). 155–155. 36 indexed citations

18.

Smith, B. Douglas, Ivana Gojo, Margaret M. Showel, et al.. (2016). Structural Chromosomal Changes Are Common Manifestation of FLT3 ITD Relapse and Presence of Chromosomal Progression Is Independent of Normal Karyotype at Diagnosis. Blood. 128(22). 2868–2868. 1 indexed citations

19.

Brissot, Éolia, Sawa Ito, B. Douglas Smith, et al.. (2014). T Cell Exhaustion and Downregulation of Cytotoxic NK Cells – an Immune Escape Mechanism in Adult Acute Lymphoblastic Leukemia. Blood. 124(21). 3781–3781. 1 indexed citations

20.

Lu, Qin, B. Douglas Smith, Hua-Ling Tsai, et al.. (2013). Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. Blood Cancer Journal. 3(9). e145–e145. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact